AU2017270219B2 - Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules - Google Patents

Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules Download PDF

Info

Publication number
AU2017270219B2
AU2017270219B2 AU2017270219A AU2017270219A AU2017270219B2 AU 2017270219 B2 AU2017270219 B2 AU 2017270219B2 AU 2017270219 A AU2017270219 A AU 2017270219A AU 2017270219 A AU2017270219 A AU 2017270219A AU 2017270219 B2 AU2017270219 B2 AU 2017270219B2
Authority
AU
Australia
Prior art keywords
soft gel
capsule
gel capsule
liquid formulation
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017270219A
Other languages
English (en)
Other versions
AU2017270219A1 (en
Inventor
Lingwei DAI
Jie Gu
Ralf Jaeger
Martin Purpura
Zheng XIONG
Yaohua Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsi Group Co Ltd
Original Assignee
Tsi Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsi Group Co Ltd filed Critical Tsi Group Co Ltd
Publication of AU2017270219A1 publication Critical patent/AU2017270219A1/en
Assigned to TSI GROUP CO., LTD. reassignment TSI GROUP CO., LTD. Request for Assignment Assignors: TSI Group Ltd.
Application granted granted Critical
Publication of AU2017270219B2 publication Critical patent/AU2017270219B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2017270219A 2016-05-25 2017-05-25 Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules Active AU2017270219B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341464P 2016-05-25 2016-05-25
US62/341,464 2016-05-25
PCT/US2017/034551 WO2017205673A1 (en) 2016-05-25 2017-05-25 Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules

Publications (2)

Publication Number Publication Date
AU2017270219A1 AU2017270219A1 (en) 2018-11-29
AU2017270219B2 true AU2017270219B2 (en) 2023-03-16

Family

ID=60411620

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017270219A Active AU2017270219B2 (en) 2016-05-25 2017-05-25 Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules

Country Status (12)

Country Link
US (3) US10959957B2 (enExample)
EP (1) EP3463327B1 (enExample)
JP (1) JP6929939B2 (enExample)
KR (1) KR102384266B1 (enExample)
CN (2) CN121177244A (enExample)
AU (1) AU2017270219B2 (enExample)
CA (1) CA3024584A1 (enExample)
CO (1) CO2018014085A2 (enExample)
MX (1) MX2018014407A (enExample)
MY (1) MY199597A (enExample)
RU (1) RU2018145520A (enExample)
WO (1) WO2017205673A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111888325A (zh) * 2020-08-04 2020-11-06 瑞希(重庆)生物科技有限公司 一种卡拉胶凝胶、药物赋形剂和皮肤外用制剂
JP7750505B2 (ja) * 2021-10-14 2025-10-07 中日本カプセル 株式会社 カプセル及びカプセルの製造方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870062A (en) * 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
EP1105107A1 (en) * 1999-07-07 2001-06-13 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US20080031964A1 (en) * 2005-02-15 2008-02-07 Jallal Messadek Combination therapeutic compositions and method of use
US20120053240A1 (en) * 2009-12-18 2012-03-01 Metabolic Technologies, Inc. Method of Administering beta-hydroxy-beta-methylbutyrate (HMB)
US20140080781A1 (en) * 2012-09-10 2014-03-20 Metabolic Technologies, Inc. Composition of HMB and ATP and Methods of Use
WO2014152098A1 (en) * 2013-03-15 2014-09-25 Banner Pharmacaps Inc. Non-gelatin enteric soft capsules
WO2015094925A1 (en) * 2013-12-18 2015-06-25 Capsugel Belgium Nv Stable liquid filled hard capsule comprising beta-hydroxy-beta-methylbutyric acid
US20150342914A1 (en) * 2011-07-15 2015-12-03 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200191A (en) 1991-09-11 1993-04-06 Banner Gelatin Products Corp. Softgel manufacturing process
US5569466A (en) 1995-05-17 1996-10-29 R. P. Scherer Corporation Fill compositions for soft elastic gel capsules
DE10064312C2 (de) 2000-12-22 2003-05-22 Degussa Cholinpyruvat-Hydrat, Verfahren zu dessen Herstellung, Cholinpyruvat-Hydrat enthaltende Formulierung sowie deren Verwendung
US7740878B2 (en) * 2001-10-22 2010-06-22 Danisco A/S Use of betaine to enhance exercise performance
ES2294197T3 (es) 2001-12-21 2008-04-01 Supernus Pharmaceuticals, Inc. Formulacion de capsula oral con estabilidad fisica aumentada.
DE10208568A1 (de) 2002-02-27 2003-09-18 Degussa Bioactives Deutschland Verbindung, enthaltend Kreatin, eine Säure-Komponente und/oder einen Komplex-Bildner
DE10217557A1 (de) 2002-04-19 2003-11-06 Degussa Bioactives Gmbh Funktionsnahrungsmittel enthaltend eine Phospholipid-haltige stabile Matrix
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US8231896B2 (en) * 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
DE102004060914A1 (de) 2004-12-17 2006-07-06 Bioghurt Biogarde Gmbh & Co. Kg Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen
DE102005061765A1 (de) 2005-05-19 2006-11-23 Degussa FreshTech Beverages LLC, Milwaukee Füllmaterial für einen Getränkebehälter
CN101574146B (zh) * 2008-05-07 2012-06-13 北京康比特体育科技股份有限公司 一种含有hmb的运动营养补剂
JP2009153529A (ja) 2009-04-17 2009-07-16 Tsujido Chemical Corp 食品組成物
MX2013007347A (es) 2010-12-22 2013-08-01 Abbott Lab Productos nutricionales que comprenden beta-hidroxi-beta metilbutirato de calcio y acido linoleico conjugado.
AU2013344753B2 (en) 2012-11-13 2018-09-27 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
US20140272000A1 (en) 2013-03-14 2014-09-18 Metabolic Technologies, Inc. Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same
JP2016520050A (ja) 2013-05-01 2016-07-11 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 老化筋肉再生の増強方法
US20150366813A1 (en) * 2014-06-20 2015-12-24 Banner Life Sciences Llc Liquid-filled immediate release soft gelatin capsules
JP2018090504A (ja) * 2016-11-30 2018-06-14 株式会社東洋新薬 筋肉増強用組成物

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870062A (en) * 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
EP1105107A1 (en) * 1999-07-07 2001-06-13 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US20080031964A1 (en) * 2005-02-15 2008-02-07 Jallal Messadek Combination therapeutic compositions and method of use
US20120053240A1 (en) * 2009-12-18 2012-03-01 Metabolic Technologies, Inc. Method of Administering beta-hydroxy-beta-methylbutyrate (HMB)
US20150342914A1 (en) * 2011-07-15 2015-12-03 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
US20140080781A1 (en) * 2012-09-10 2014-03-20 Metabolic Technologies, Inc. Composition of HMB and ATP and Methods of Use
WO2014152098A1 (en) * 2013-03-15 2014-09-25 Banner Pharmacaps Inc. Non-gelatin enteric soft capsules
US20160038425A1 (en) * 2013-03-15 2016-02-11 Banner Life Sciences Llc Non-Gelatin Enteric Soft Capsules
WO2015094925A1 (en) * 2013-12-18 2015-06-25 Capsugel Belgium Nv Stable liquid filled hard capsule comprising beta-hydroxy-beta-methylbutyric acid

Also Published As

Publication number Publication date
EP3463327A4 (en) 2020-01-22
US20250057773A1 (en) 2025-02-20
KR20190021259A (ko) 2019-03-05
RU2018145520A3 (enExample) 2020-08-26
MX2018014407A (es) 2019-02-21
EP3463327A1 (en) 2019-04-10
EP3463327C0 (en) 2024-04-17
RU2018145520A (ru) 2020-06-25
US12133920B2 (en) 2024-11-05
KR102384266B1 (ko) 2022-04-06
WO2017205673A1 (en) 2017-11-30
JP2019517576A (ja) 2019-06-24
CN121177244A (zh) 2025-12-23
CO2018014085A2 (es) 2019-03-18
US10959957B2 (en) 2021-03-30
CA3024584A1 (en) 2017-11-30
JP6929939B2 (ja) 2021-09-01
US20170340572A1 (en) 2017-11-30
BR112018073949A2 (pt) 2019-02-26
US20210212953A1 (en) 2021-07-15
AU2017270219A1 (en) 2018-11-29
MY199597A (en) 2023-11-08
BR112018073949A8 (pt) 2023-03-21
EP3463327B1 (en) 2024-04-17
CN109562087A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
US20250057773A1 (en) Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules
US10188611B2 (en) Stable liquid filled hard capsule comprising beta-hydroxy-beta methylbutyric acid
KR910000028B1 (ko) 제약 혼합제의 제조방법
CZ291637B6 (cs) Farmaceutický prostředek
JP2013209416A (ja) 胃の逆流抵抗性投薬形態
EP3796896B1 (en) PHARMACEUTICAL COMPOSITION OF ADRENALINE
JP2024109878A (ja) 液体ベンダムスチン医薬組成物
US7029698B2 (en) Acetaminophen compositions
KR20120062208A (ko) 홍삼 오일을 부형제 오일로 함유하는 연질캡슐제
CN103191079A (zh) 一种胞磷胆碱钠片及其制备方法
TWI650133B (zh) 含有米卡芬淨或其鹽的醫藥組成物
HK40005738A (en) Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules
BR112018073949B1 (pt) Cápsula gelatinosa mole de ácido hidroxil-3-metilbutírico, e, método para formar uma cápsulagelatinosa mole de ácido hidroxil-3-metilbutírico
US20120094951A1 (en) Compositions
CN105395512A (zh) 一种盐酸环苯扎林控释片
BRPI0519466B1 (pt) dispersão sólida estável de um derivado de alcalóide de vinca e processo para a fabricação do mesmo
TWI634897B (zh) 米卡芬淨或其鹽的醫藥組成物
IT201800003615A1 (it) Formulazioni altamente stabili di ormone tiroideo in capsule molli
KR101346750B1 (ko) 나프록센 액상 조성물을 함유하는 밀봉된 경질캡슐제
US20170239187A1 (en) Stable dosage form articles for oral administration
KR20110133889A (ko) 덱시부프로펜 액상 조성물을 함유하는 밀봉된 경질캡슐제
EA042077B1 (ru) Сухая порошкообразная фармацевтическая композиция для ингаляции, содержащая тиреоидный гормон
EA041152B1 (ru) Пероральное лекарственное средство для щитовидной железы
TR201603780A1 (tr) Sfi̇ngozi̇n-1 fosfat reseptör agoni̇sti̇ i̇çeren formülasyonlar

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TSI GROUP CO., LTD.

Free format text: FORMER APPLICANT(S): TSI GROUP LTD.

FGA Letters patent sealed or granted (standard patent)